The Insulin Maker That Became a Trillion-Dollar Bet on Metabolism

In 1876, a Civil War colonel named Eli Lilly opened a small drug laboratory in Indianapolis because he was tired of the useless, poorly made medicines of his day. He promised himself the products would be built on the best science available. A century and a half later, the company that still carries his signature as its logo is worth close to a trillion dollars - and the thing driving it is a weekly injection that helps people manage diabetes and lose weight.

That is the strange, satisfying arc of Eli Lilly and Company. It has spent 150 years being famous for different molecules in different eras - insulin in the 1920s, Prozac in the 1980s, Cialis in the 2000s - and it keeps arriving, on schedule, with the drug that defines the decade. Right now that drug is tirzepatide, and it is reshaping not just Lilly's balance sheet but the way an entire culture thinks about weight.

What it actually doesA drug factory with a research habit

Strip away the branding and Lilly is a research-driven pharmaceutical company. It discovers molecules, runs them through years of clinical trials, wins regulatory approval, then manufactures and sells them in roughly 90 countries. The medicines cluster in a few high-stakes areas: cardiometabolic disease (diabetes and obesity), oncology, immunology and neuroscience. It also still makes the insulin franchises - Humalog and Humulin - that put it on the map.

What separates Lilly from a generic-drug maker is where the money goes. About one in four of its roughly 51,000 employees works in research and development. That is not a department; it is a small city of scientists whose entire job is to find the next molecule before the current one loses patent protection.

The molecule that ate the balance sheetOne drug, two names

Here is the fact that surprises people: Mounjaro and Zepbound are the same drug. Both are tirzepatide, a molecule that mimics two gut hormones, GIP and GLP-1, to blunt appetite and improve blood-sugar control. Lilly sells it under Mounjaro for type 2 diabetes and under Zepbound for chronic weight management and obesity-related sleep apnea. Same compound, two doors into the market.

The combined franchise did about $36.5 billion in sales in 2025 - roughly 56% of everything the company earned. In the first quarter of 2026, Mounjaro revenue grew 125% to $8.7 billion in a single quarter. Growth like that is rare enough that Lilly's actual constraint stopped being demand and became supply: it has been pouring billions into new factories to make enough of the drug.

Who it is forPatients, and everyone who pays for them

Lilly's customers are patients and the physicians who prescribe to them, but its money flows through a longer chain: wholesalers, pharmacies, hospitals, insurers, pharmacy-benefit managers and government health programs. In diabetes and obesity alone, the tirzepatide franchise now serves millions of people. Across all of its therapies, the company touches tens of millions of patients a year.

That reach comes with a tension the company has faced since the insulin days. A blockbuster only matters if people can get it, and Lilly runs patient-assistance programs, including the Lilly Cares Foundation, alongside a business built on premium-priced, patent-protected drugs. Even now, its filings note that soaring volumes for the new metabolic drugs are partly offset by lower realized prices - the affordability question never fully goes away.

The portfolioMore than one blockbuster at a time

Most pharmaceutical companies would trade a decade for a single drug like Zepbound. Lilly is running several at once - a spread across metabolism, cancer, the brain and the immune system.

The 2026 approval of orforglipron - marketed as Foundayo - matters more than another line on the list. If injectable GLP-1s built a trillion-dollar company, a daily pill that does something similar could be the sequel, reaching people who will never accept a needle. It is the clearest sign that Lilly intends to defend the metabolic market it helped create.

The expertise150 years of picking the right molecule

Lilly's real asset is institutional know-how in turning biology into approved, manufacturable drugs. It was among the first companies to mass-produce insulin in the 1920s, working from the University of Toronto's discovery, and among the first to mass-produce penicillin. In 1982 it introduced Humulin, the world's first human-health product made using recombinant DNA technology - a genuinely new way of making medicine. Prozac followed in 1988 and reshaped the treatment of depression; Cialis arrived in 2003.

That history is not nostalgia. The same core competencies - peptide and antibody engineering, large-molecule manufacturing at scale, running enormous global clinical trials - are exactly what tirzepatide, donanemab and orforglipron require today. The company spun off its animal-health division, Elanco, in 2019 to concentrate entirely on human pharmaceuticals, and the focus has paid off in the metabolic era.

How it is differentTwo companies, one market

The obesity-and-diabetes boom is essentially a two-horse race, and Lilly's defining rival is Denmark's Novo Nordisk, maker of Ozempic and Wegovy (semaglutide). The pair have split the GLP-1 market between them, competing on efficacy data, dosing, oral versus injectable formats, and sheer manufacturing capacity. Across oncology, immunology and neuroscience, Lilly also spars with Pfizer, Merck, AbbVie, Johnson & Johnson, Novartis, AstraZeneca, Amgen and Roche.

What sets Lilly apart in this cycle is less a single strategy than a track record of timing. It has repeatedly arrived with the category-defining drug and then poured capital into making enough of it - the unglamorous manufacturing arms race that decides who actually captures a market when demand outstrips supply.

How the money worksPatents, pipelines and acquisitions

The business model is the classic branded-pharma engine, run at scale. Lilly invests heavily in internal R&D and in buying smaller biotechs to refill its pipeline - Loxo Oncology anchored its precision-cancer work, Point Biopharma brought radioligand therapies, and Prevail Therapeutics extended it into gene therapy for neurodegenerative disease. Approved drugs enjoy patent-protected pricing for a window of years; the whole system runs on replacing revenue before those patents expire.

In 2025 alone the company reported more than 25 Phase 3 programs with positive topline results and initiated dozens of new discovery programs - the raw material for the next decade of products. Revenue reached $65.18 billion for 2025, and after strong first-half 2026 results the company raised its full-year guidance to between $85 billion and $87 billion.

Where it sitsA trillion-dollar drugmaker in a small city

By market value, Lilly has spent stretches of 2024 through 2026 as the most valuable healthcare company in the world, trading near a $1.08 trillion capitalization. That scale belongs to a company still run from Indianapolis, where it has been headquartered without interruption for 150 years and where more than 13,000 of its employees still work.

There is a continuity to it that most trillion-dollar stories lack. The logo is a dead man's signature. The founding family's philanthropic vehicle, the Lilly Endowment, remains a major shareholder. And the company keeps doing the thing Colonel Lilly set out to do in 1876 - make medicines that work, on the best science available - only now the science is engineered peptides and the market is the whole planet's metabolism.

The long viewWhat it can do for you

For a patient, Lilly is the maker of the prescription that might manage your diabetes, shrink a tumor's growth, quiet an autoimmune flare, slow early Alzheimer's, or help with obesity that diet alone never touched. For an investor, it is one of the few megacap companies still compounding at a growth-stock pace. For anyone watching how modern medicine gets made, it is a live case study in reinvention - a 150-year-old firm that refuses to be defined by the drug that made it famous last.